These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28864095)

  • 1. Minimal residual disease in chronic lymphocytic leukaemia.
    García Vela JA; García Marco JA
    Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
    Thompson M; Brander D; Nabhan C; Mato A
    JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
    Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
    J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
    Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin MD; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CU; Kater AP
    J Clin Oncol; 2023 Jul; 41(21):3689-3699. PubMed ID: 37279408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
    Munir T; Emmerson J; Hockaday A; Oughton JB; Howard D; Phillips D; Neilson J; Pemberton N; Paneesha S; Kennedy B; Rawstron A; Hillmen P
    Br J Haematol; 2022 Dec; 199(5):707-719. PubMed ID: 36017875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of Minimal Residual Disease in the Era of Targeted Agents.
    Heltai S; Ghia P; Scarfò L
    Cancer J; 2019; 25(6):410-417. PubMed ID: 31764122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
    Owen C; Christofides A; Johnson N; Lawrence T; MacDonald D; Ward C
    Leuk Lymphoma; 2017 Dec; 58(12):2777-2785. PubMed ID: 28509580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
    Fürstenau M; Weiss J; Giza A; Franzen F; Robrecht S; Fink AM; Fischer K; Schneider C; Tausch E; Stilgenbauer S; Ritgen M; Schilhabel A; Brüggemann M; Eichhorst B; Hallek M; Cramer P
    Clin Cancer Res; 2022 Oct; 28(19):4203-4211. PubMed ID: 35594173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
    Thompson PA; Wierda WG
    Blood; 2016 Jan; 127(3):279-86. PubMed ID: 26576865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.
    Tomuleasa C; Selicean C; Cismas S; Jurj A; Marian M; Dima D; Pasca S; Petrushev B; Moisoiu V; Micu WT; Vischer A; Arifeen K; Selicean S; Zdrenghea M; Bumbea H; Tanase A; Grewal R; Pop L; Aanei C; Berindan-Neagoe I
    Crit Rev Clin Lab Sci; 2018 Aug; 55(5):329-345. PubMed ID: 29801428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
    Wang XV; Hanson CA; Tschumper RC; Lesnick CE; Braggio E; Paietta EM; O'Brien S; Barrientos JC; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Erba H; Stone R; Litzow MR; Tallman MS; Shanafelt TD; Kay NE
    Blood; 2021 Dec; 138(26):2810-2827. PubMed ID: 34407545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
    Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
    Front Oncol; 2019; 9():689. PubMed ID: 31555576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
    García-Marco JA; Delgado J; Hernández-Rivas JA; Ramírez Payer Á; Loscertales Pueyo J; Jarque I; Abrisqueta P; Giraldo P; Martínez R; Yáñez L; Terol MJ; González M; Bosch F;
    Med Clin (Barc); 2017 Apr; 148(8):381.e1-381.e9. PubMed ID: 28236475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of minimal residual disease in chronic lymphocytic leukemia.
    Schweighofer CD; Hallek M; Wendtner CM
    Curr Hematol Malig Rep; 2008 Jan; 3(1):54-60. PubMed ID: 20425447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
    Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
    Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
    Cramer P; von Tresckow J; Bahlo J; Engelke A; Langerbeins P; Fink AM; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst B; Hallek M
    Future Oncol; 2018 Mar; 14(6):499-513. PubMed ID: 29465308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.
    Rios-Olais FA; Hilal T
    Curr Treat Options Oncol; 2023 Aug; 24(8):907-928. PubMed ID: 37195588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
    Langerak AW; Ritgen M; Goede V; Robrecht S; Bahlo J; Fischer K; Steurer M; Trněný M; Mulligan SP; Mey UJM; Trunzer K; Fingerle-Rowson G; Humphrey K; Stilgenbauer S; Böttcher S; Brüggemann M; Hallek M; Kneba M; van Dongen JJM
    Blood; 2019 Jan; 133(5):494-497. PubMed ID: 30455380
    [No Abstract]   [Full Text] [Related]  

  • 20. [Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].
    Plander M; Skrapits J; Bozsó T; Szendrei T; Iványi JL
    Orv Hetil; 2012 Oct; 153(41):1622-8. PubMed ID: 23045312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.